CD52 inhibitors(CAMPATH-1 antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [2]

Active Indication

T-Cell Prolymphocytic LeukemiaHematopoietic stem cell transplantationMultiple Sclerosis, Relapsing-Remitting+ [3]

Inactive Indication

Acute Myeloid LeukemiaAdult T-Cell Leukemia-LymphomaAdvanced Marginal Zone Lymphoma+ [35]

Originator Organization

Genzyme Corp.

Active Organization

Sanofi-Aventis Australia Pty Ltd.

Cellectis SA

Genzyme Corp.

+ [3]

Inactive Organization

Bayer AGSanofi BV

Astex Pharmaceuticals, Inc.

+ [1]

License Organization

Bayer Pharma AG

Genzyme Corp.

Sanofi

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (07 May 2001),

Chronic Lymphocytic LeukemiaMultiple Sclerosis

RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Structure/Sequence

Sequence Code 53002L

Source: *****

Sequence Code 53009H

Source: *****

345

Clinical Trials associated with Alemtuzumab

NCT07616154

/ Not yet recruitingPhase 2IIT

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD.
Primary Objective:
- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD.
Secondary Objectives:
* Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD.
* Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD.
* Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.

Start Date01 Sep 2026

Sponsor / Collaborator

St. Jude Children's Research Hospital, Inc.

NCT06084780

/ Not yet recruitingPhase 2IIT

Prospective Case Series of Intestinal and Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.

Start Date01 Aug 2026

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT07599176

/ RecruitingPhase 1/2IIT

Matched Related Donor Non-myeloablative Hematopoietic Cell Transplantation With Alemtuzumab, 400 cGy TBI, and Abatacept for Sickle Cell Disease and Beta-Thalassemia

This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.

Start Date08 Jul 2026

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Alemtuzumab

100 Translational Medicine associated with Alemtuzumab

100 Patents (Medical) associated with Alemtuzumab

3,061

Literatures (Medical) associated with Alemtuzumab

01 Sep 2026·CLINICAL NEUROLOGY AND NEUROSURGERY

Lymphopenia predicts infectious complications after alemtuzumab therapy in multiple sclerosis: Real-world experience from a Brazilian cohort

Article

Author: de Holanda, Arthur Cesário ; Pereira, Samira Luísa Apóstolos ; Tejo, Alexandre Mestre ; Tonacio, Adriana Coracini ; Callegaro, Dagoberto ; Silva, Guilherme Diogo ; Adoni, Tarso

OBJECTIVE:

Alemtuzumab, a humanized monoclonal anti-CD52 antibody, is an effective therapy for relapsing multiple sclerosis (MS) but is associated with an increased risk of infections. Real-world safety data from tropical and middle-income settings remain limited. We aimed to evaluate infectious complications after alemtuzumab therapy and identify clinical predictors of infection.

METHODS:

We performed a retrospective analysis of a prospectively maintained database of all MS patients receiving a first course of alemtuzumab at the largest public hospital in Brazil between February 2023 and August 2024. Clinical and laboratory data were collected through monthly follow-up.

RESULTS:

Forty-four patients received alemtuzumab, and 29 (65.9%) developed at least one infectious episode, totaling 47 events. Most infections were mild, predominantly upper respiratory (33.9%) and urinary tract infections (25.5%). Three hospitalizations occurred, with no deaths. Infection risk increased during periods of lower lymphocyte counts. In a generalized estimating equation model adjusted for follow-up month, lymphocyte counts below 500 cells/μL were associated with higher odds of infection during the corresponding monthly interval (OR 3.69; 95% CI 1.70-7.98; p = 0.0009). Leukocyte and neutrophil counts were not associated with infection occurrence.

CONCLUSION:

In this real-world cohort, infectious events after alemtuzumab were common but mostly mild. Lymphocyte counts below 500 cells/μL identified periods of increased infection risk, supporting intensified clinical and laboratory monitoring during immune depletion.

01 Jul 2026·Multiple Sclerosis and Related Disorders

Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis

Review

Author: Maheshwari, Vikalp ; Saipriya, J ; Harty, Gerard T ; Jones, Michelle

BACKGROUND:

To update previous work assessing the relative efficacy and safety of cladribine tablets compared to currently approved disease-modifying treatments (DMTs) in patients with active relapsing-remitting multiple sclerosis (RRMS), using systematic literature review (SLR) and network meta-analysis (NMA).

METHODS:

Systematic literature searches were conducted in MEDLINE, Embase, MEDLINE In-Process and CENTRAL databases to identify English-language publications of relevant studies of approved DMTs for RRMS. Searches were conducted from database inception to January 2017, and then further updated from January 2017 to September 2022. Conference websites and trial registries were also searched. NMA considered the effects of DMTs on annualized relapse rate (ARR), confirmed disease progression (CDP), proportion relapse-free (RF), and safety.

RESULTS:

Of 21,181 unique articles retrieved and screened, 66 studies met the inclusion criteria and had their data extracted, including 17 new studies since the previous review; of these, 57 studies assessing 20 DMTs contributed to the NMA. In patients with active RRMS, cladribine tablets were associated with a significant 58% reduction in ARR versus placebo; cladribine tablets were similar or significantly better than other DMT regimens. For 6-month CDP, improvements with cladribine tablets were significantly greater than those of placebo, with no comparator DMT demonstrating significantly better results. For both efficacy endpoints, cladribine tablets ranked sixth among DMTs, behind ofatumumab, ublituximab, alemtuzumab, natalizumab, and ocrelizumab. The overall adverse event risk for cladribine tablets was statistically comparable to all other oral DMTs and both interferon beta-1a regimens.

CONCLUSIONS:

In this updated SLR and NMA, cladribine tablets remain a comparatively effective and safe alternative to other currently approved DMTs in populations of patients with active RRMS.

23 Jun 2026·Blood Advances

Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study

Article

Author: Malloy, Julia ; Guilcher, Gregory M.T. ; Kent, Michael ; Hardy, Steven J. ; Ali, Muhammad ; Zhang, Anqing ; Abraham, Allistair ; Kukadiya, Divyesh ; Nickel, Robert Sheppard ; Rangarajan, Hemalatha G. ; Chaudhury, Sonali ; Odinakachukwu, Maryanne ; Chiang, Kuang-Yueh

Abstract:

HLA-identical sibling donor hematopoietic cell transplant (HCT) is an established curative therapy for sickle cell disease (SCD). Although myeloablative HCT conditioning achieves a high event-free survival (EFS) in children, it carries substantial toxicity, including risks of graft-versus-host disease (GVHD), transplant-related mortality, and infertility. Nonmyeloablative conditioning with alemtuzumab, 300 cGy total body irradiation, and sirolimus has demonstrated tolerability as a curative approach in adults with SCD. We conducted a multicenter, prospective clinical trial to evaluate this regimen in children and adolescents with SCD. Thirty-eight patients (aged 2.9-21.9 years; median age, 13.5 years) underwent HCT. All achieved initial engraftment; however, 7 patients (18.4%) experienced secondary graft failure between day +39 and day +391 with autologous hematologic reconstitution. One additional patient received an unconditioned second HCT. At 2 years after HCT, overall survival was 100%, and EFS was 78.9%. Among patients with engraftment, 2-year median donor myeloid chimerism was 95%, and T-cell chimerism was 75%. No patients developed acute or chronic GVHD. The median number of platelet transfusions received was 0 (interquartile range, 0-3). Patient-reported health-related quality of life remained stable early after HCT and significantly improved at 1 year. After year 2, 3 additional patients received a reduced-intensity second HCT to avert secondary graft failure. Although regimen modifications are needed to reduce graft failure risk, this nonmyeloablative approach offers a relatively low-toxicity curative option for children with SCD who have an HLA-identical sibling donor. This trial was registered at www.clinicaltrials.gov as NCT03587272.

News (Medical) associated with Alemtuzumab

11 Jun 2026

·www.biospace.com

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating lasme-cel in r/r B-ALL - Oral Presentation The BALLI-01 final Phase 1 data will be presented as an oral presentation by Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, TX. 45 patients in third line and beyond (3L+) were treated in the BALLI-01 study. 15 patients were treated at the recommended Phase 2 dose and 7 in the target Phase 2 population. Patients were heavily pretreated with those in the target Phase 2 population receiving a median of 5 prior lines of therapy (Range 2-11). Almost all patients were previously treated with blinatumumab (82%) and were also heavily exposed to CD19 CAR-T (53%), CD22-directed antibody-drug conjugate (ADC) (56%) and many had a prior hematopoietic stem cell transplantation (HSCT) (47%). Final Phase 1 data In the target Phase 2 population An overall response rate (ORR) of 100% (7/7) was achieved with a complete remission/complete remission with incomplete count recovery (CR/CRi) rate of 57% (4/7). Of these, 75% achieved minimal residual disease negative (MRD-ve) status. All patients subsequently proceeded to HSCT. Lasme-cel demonstrated a manageable safety profile Cytokine release syndrome (CRS) ≥ grade 3 occurred in 4% of patients. Immune effector cell-associated neurotoxicity syndrome (ICANS) ≥ grade 3 occurred in 4% of patients. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) ≥ grade 3 occurred in 2% of patients. All CRS, ICANS, and IEC-HS resolved. “These final Phase 1 results are particularly meaningful for a patient population that has very limited treatment options” said Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at UT MD Anderson. “Being able to achieve deep remissions in these patients and allowing them to subsequently receive an HSCT is promising. We look forward to accelerating accrual into the ongoing Pivotal Phase 2 study and bringing this treatment to patients.” The Pivotal Phase 2 BALLI-01 trial is open for recruitment. Eligible patients and treating physicians are encouraged to visit BALLI-01 (NCT04150497) or contact Cellectis at clinicaltrials@cellectis.com for information and participating sites. The first interim analysis is expected in Q4 2026. Oral Presentation: Safety and efficacy of UCART22 in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL): results of the Phase 1 BALLI-01 trial Date/Time: Saturday, June 13 at 5:15 - 6:30pm, local time Session Title: Advances in the treatment of lymphoblastic leukemia Session Room: K1 Abstract Number: 4689 Note: presentation slides will be uploaded to Cellectis’ website concurrently with the live presentation. NATHALI-01 clinical trial evaluating eti-cel in r/r B-NHL - Poster Presentation The NATHALI-01 preliminary data on the role of alemtuzumab in optimizing responses will be presented as a poster by Professor Emmanuel Bachy, M.D., Ph.D., Department of Hematology, Hospices Civils de Lyon, France. Eti-cel is a highly differentiated product being the first allogeneic dual CAR-T targeting both CD20 and CD22, for patients with r/r B-NHL. As of the February 2026 data cutoff, 14 patients with r/r B-NHL had been treated across three dose levels, in a heavily pre-treated population with a median of 3 prior lines of therapy, 93% of whom had received prior CD19-directed CAR-T therapy, and all of whom presented with stage IV disease at baseline. In the optimal dose cohort, ORR and complete response (CR) were 88% and 63%, respectively. The analysis identified a positive correlation between alemtuzumab exposure and clinical outcomes: higher alemtuzumab exposure created a favorable lower inflammatory homeostatic milieu prior to eti-cel infusion and was associated with enhanced eti-cel expansion and higher response rates. Additionally, responders maintained sustained low-level interleukin 2 (IL-2) secretion when compared to non-responders. These findings provide a scientific rationale for the implementation of a weight-based alemtuzumab dosing regimen, currently under investigation to optimize lymphodepletion. Additionally, subcutaneous low-dose IL-2 is being investigated to further enhance eti-cel expansion and treatment response. “These encouraging data demonstrate that not only can eti-cel drive responses in a very difficult-to-treat population, but that by optimizing exposure to alemtuzumab we may be able to create a favorable environment for CAR-T expansion and persistence. " said Professor Emmanuel Bachy, M.D., Ph.D., Department of Hematology, Hospices Civils de Lyon, France. The NATHALI-01 study is open for recruitment with the full Phase 1 clinical data expected in Q4 2026. Poster Presentation: Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study Date/Time: Saturday, June 13 at 6:45 - 7:45pm, local time Session: Poster Session 2 Poster Number: 4758 Note: poster presentation will be uploaded to Cellectis’ website at the opening of the poster session. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on LinkedIn and X . Cautionary Statement This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “can,” “expected,” ”look-forward,” “may” or the negative of these and/or similar expressions. These forward-looking statements are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of the pivotal Phase 2 BALLI-01 trial to be a registrational phase, the advancement, timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data and submission of regulatory filings, the sufficiency of cash to fund operations, the potential benefit of our product candidates. These forward-looking statements are made in light of information currently available to us and are subject to significant risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. Among these are significant risks that the BALLI-01 Phase 1 data may not be validated by data from later stage of clinical trials and that our product candidate may not receive regulatory approval for commercialization. Particular caution should be exercised when interpreting results from Phase 1 studies and results relating to a small number of patients – such results should not be viewed as predictive of future results. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2025 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC’s website at , as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,  media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93       Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer,  investors@cellectis.com Attachment Press release_data_EHA_2026_ENGLISH

Clinical ResultImmunotherapyPhase 1Cell TherapyPhase 2

12 May 2026

·www.biospace.com

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA) annual congress, on June 11-14, 2026, in Stockholm, Sweden. Lasme-cel – Oral Presentation The abstract reporting the full Phase 1 dataset from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T, in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL), has been selected for oral presentation. These data, which will be presented by Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at MD Anderson Cancer Center in Houston (TX), highlight the promising safety pro response rates in patients who have relapsed following multiple prior targeted therapies including autologous CD19 CAR-T. They form the basis for the pivotal Phase 2 program which is currently recruiting in Europe and North America. "We are delighted to present these important data at EHA. The patients in the BALLI-01 trial had largely exhausted treatment options and faced a very poor prognosis. The depth of response we observed offers hope for these patients and demonstrates the potential for lasme-cel to become an effective therapeutic option for those with the highest unmet need. We are pursuing our pivotal Phase 2 program and plan to share the first interim analysis later this year," said Adrian Kilcoyne, M.D., MPH, MBA, Chief Medical Officer at Cellectis. The BALLI-01 trial is currently recruiting in Pivotal Phase 2 with interim data expected to be disclosed in Q4 2026. Oral Presentation: Safety and efficacy of UCART22 in heavily pre-treated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL): results of the Phase 1 BALLI-01 trial Presenter: Nitin Jain, M.D., Professor of Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston (TX) Session Title: Advances in the treatment of lymphoblastic leukemia Session Room: K1 Live Session Date and Time: Saturday, June 13 at 5:15 – 6:30pm CET Eti-cel – Poster Presentation The abstract from the Phase 1 NATHALI-01 study evaluating eti-cel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) has been accepted for poster presentation. This preliminary analysis explores the relationship between alemtuzumab exposure, eti-cel cellular expansion, cytokine dynamics, and clinical outcomes, providing early mechanistic insights into the optimization of the lymphodepletion regimen for this best-in-class dual-targeting CD20/CD22 allogeneic CAR T-cell product. The Phase 1 clinical data of the NATHALI-01 clinical trial are planned to be disclosed in Q4 2026. Poster Presentation: Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study Presenter: Professor Emmanuel Bachy, M.D., Ph.D., Department of Clinical Hematology, Lyon Sud Hospital, Lyon, France. Session: Poster Session 2 Poster Number: 4758 Session Date and Time: Saturday, June 13 at 6:45 - 7:45pm CET The abstracts are published on the EHA website . The presentations will be available on Cellectis’ website on June 11, 2026, at 8 am CET. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on LinkedIn and X . Cautionary Statement This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “become,” “expected,” “ ‘plan,” “planned,” “potential,” or “will” or the negative of these and similar expressions. These forward-looking statements are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of the pivotal Phase 2 BALLI-01 trial to be a registrational phase, the advancement, timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentations of data and submissions of regulatory filings the potential benefit of our product candidates and technologies. These forward-looking statements are made in light of information currently available to us and are subject to significant risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. Among these are significant risks that the BALLI-01 Phase 1 data may not be validated by data from later stage of clinical trials and that our product candidate may not receive regulatory approval for commercialization. Particular caution should be exercised when interpreting results from Phase 1 studies and results relating to a small number of patients – such results should not be viewed as predictive of future results. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2025 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC’s website at , as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com Attachment 20260512_EHA PR

Phase 1Phase 2Gene TherapyImmunotherapyCell Therapy

01 May 2026

·www.fiercebiotech.com

Chutes & Ladders—Astellas appoints new top strategist from Sanofi Japan

None\n Welcome to this week\'s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Zoey Becker and it will be featured here at the end of each week.Astellas appoints new top strategist from Sanofi JapanAstellas Pharma After last month’s departure of longtime executive Adam Pearson, Astellas has picked out a new strategist to fill the open spot on its C-suite with Takahiko Iwaya, who takes over as chief strategy officer on July 1. Before embarking on a career within biopharma leadership, Iwaya joined what is now Japan’s Ministry of Health, Labour and Welfare in 1990, where he worked on healthcare systems and policies for 14 years. After that, the executive held various leadership positions at Johnson & Johnson Japan before joining Sanofi’s Japan unit in 2019. In June, the executive will step down from his current role as president and representative director at Sanofi Japan, as well as depart his role as chair of the European Federation of Pharmaceutical Industries and Associations, Japan. He takes over the strategy role at Astellas from Peter Sandor, M.D., who has been holding down the fort on an interim basis since Pearson’s resignation. ReleaseImmunic preps for approval push with pharma vetImmunicAs a critical phase 3 readout for its multiple sclerosis candidate rapidly approaches, Immunic is shoring up its leadership with Michael Panzara, M.D., as chief medical officer. Panzara previously oversaw the approvals of other MS medicines like Biogen’s Tysabri and Sanofi’s Lemtrada and Aubagio. Panzara takes over for the departing Andreas Muehler, M.D., who is also a co-founder of Immunic. Immunic’s vidofludimus calcium is currently being tested in a pair of phase 3 trials, though the candidate previously failed to hit the primary endpoint of a phase 2 study. ReleaseCardiologist turns new leaf at NuevocorNuevocorCardio-focused Nuevocor is making a hearty change to its C-suite, bringing in experienced cardiologist Monica Shah, M.D., as chief medical officer. Shah brings a wealth of cell and gene therapy experience, including stints leading the global AAV program at Rocket Pharmaceuticals and the cell and gene therapy division of IQVIA. She built her career with a nearly nine-year tenure at the National Institutes of Health, mostly as the deputy chief of heart failure and arrhythmias at the National Heart, Lung, and Blood Institute. Nuevocor is counting on Shah to guide first-in-human studies of NVC-001, the biotech’s lead gene therapy for cardiomyopathy. Release> AI-focused vaccine maker Evaxion is opting for a dual role for chief scientific officer Birgitte Rønø, who has now been promoted to chief operating officer as well. Release> Convergent Therapeutics is bringing in seasoned dealmaker Andrew Davis to serve as chief business and strategy officer. Release> Longtime CEO Eric Goupil is handing over the reins at global contract manufacturer Unither Pharmaceuticals, with Henrik Krüpper lined up to take his place on May 4. Release> Hot off a deal with Merck & Co., antibody outfit Infinimmune is upping its pipeline tactics with Anthony Slavin, Ph.D., as senior vice president of portfolio strategy. Release> British cell and gene CDMO eXmoor Pharma is welcoming former Catalent CEO George Fotiades as chair, while founder Angela Osborne steps back from the role. Release> Synthetic biology specialist Manus Bio has named Baljit Ghotra, Ph.D., as senior vice president of innovation and operations. Release

Executive ChangePhase 3

100 Deals associated with Alemtuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
D02802	Alemtuzumab	L04AA34	DB00087

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
T-Cell Prolymphocytic Leukemia	Japan	Sanofi KK	18 May 2026
Hematopoietic stem cell transplantation	Japan	Sanofi KK	26 Sep 2014
Multiple Sclerosis, Relapsing-Remitting	European Union	Sanofi	12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting	Iceland	Sanofi	12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting	Liechtenstein	Sanofi	12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting	Norway	Sanofi	12 Sep 2013
Chronic Lymphocytic Leukemia	United States	Genzyme Corp.	07 May 2001
Multiple Sclerosis	United States	Genzyme Corp.	07 May 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 3	Israel	Bayer AG	01 Jul 2004
Myelodysplastic Syndromes	Phase 3	Israel	Bayer AG	01 Jul 2004
B-Cell Leukemia	Phase 3	United States	Genzyme Corp.	01 Jul 2001
CD22 Positive B-cell Acute Lymphoblastic Leukemia	Phase 2	United States	Cellectis SA	14 Oct 2019
CD22 Positive B-cell Acute Lymphoblastic Leukemia	Phase 2	France	Cellectis SA	14 Oct 2019
Philadelphia positive acute lymphocytic leukaemia	Phase 2	United States	Genzyme Corp.	01 Sep 2009
Recurrent Adult Acute Lymphoblastic Leukemia	Phase 2	United States	Genzyme Corp.	01 Sep 2009
Refractory acute lymphoid leukemia	Phase 2	United States	Genzyme Corp.	01 Sep 2009
Chronic graft-versus-host disease	Phase 2	Canada	Bayer AG	01 Oct 2008
Hematologic Neoplasms	Phase 2	Canada	Bayer AG	01 Oct 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	T-Cell Prolymphocytic Leukemia	437	Alemtuzumab IV	csxjpldacr(kyezomfimq) = Alemtuzumab IV: CMV reactivation, minor infusion reactions; Alemtuzumab SubQ: Primary refractory disease; Sequential FMC-A: 91% CMV reactivation, neutropenia; Alemtuzumab + Pentostatin: Cumulative myelosuppression; CHOP / Purine Analogs: Hematologic toxicity, rapid relapse lfhtulorqj (embssuafzi )	Positive	29 May 2026
				Alemtuzumab SubQ
EHA2026	Not Applicable	Acute Myeloid Leukemia \| Neoplasms	132	Alemtuzumab + Alemtuzumab	gmujcspvwk(elbbmtddcm) = fjjnaaowlm tmrqczyokv (zbsrvzurse )	Positive	12 May 2026
				FBM regimen + ATG	gmujcspvwk(elbbmtddcm) = zmgbvqdsxg tmrqczyokv (zbsrvzurse )
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Hematopoietic stem cell transplantation	98	Alemtuzumab	wxdbwgffwj(wnplfstdod) = odzulczifb wdgiymnajl (tcfmmbcmmr ) View more	Positive	04 Feb 2026
				Post-transplant cyclophosphamide (PTCy)	wxdbwgffwj(wnplfstdod) = fyahttfgsq wdgiymnajl (tcfmmbcmmr ) View more
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Hematopoietic stem cell transplantation	28	Alemtuzumab	tuzmaapyja(smbufpipeh) = cqauutvtnh evdxvmanvr (gpclcgwwrv ) View more	Positive	04 Feb 2026
				Post-Transplant Cyclophosphamide (PTCy)	tuzmaapyja(smbufpipeh) = lyaxssebdz evdxvmanvr (gpclcgwwrv ) View more
ASH2025	Not Applicable	Refractory Severe Aplastic Anemia	62	Alemtuzumab-based regimen	pzttqogega(qqmmksedap) = ovlbfijhsx iijlforjdr (xumpimysvz, 1 - 19) View more	Positive	06 Dec 2025
				ATG-based regimen	pzttqogega(qqmmksedap) = rlvujeimtt iijlforjdr (xumpimysvz, 5 - 27) View more
ASH2025	Not Applicable	T-Cell Prolymphocytic Leukemia	49	Alemtuzumab (transplanted before 2018)	mhhvblakvt(ftgmnatvou) = fmlxjoxysg tanxbvjyok (omculqmvpv ) View more	Positive	06 Dec 2025
				Alemtuzumab (transplanted in 2018 or later)	mhhvblakvt(ftgmnatvou) = xwdexkkdxo tanxbvjyok (omculqmvpv ) View more
UKALL14 (ASH2025)	Phase 2	Adult Acute Lymphocytic Leukemia	89	Fludarabine+Melphalan+Alemtuzumab	cltejqluxn(lstfctjzez) = mukzpbrtax tnipyeexec (xgexhkkqcs ) View more	Negative	06 Dec 2025
				Cyclophosphamide+8Gy TBI+Alemtuzumab	cltejqluxn(lstfctjzez) = czblwgqqap tnipyeexec (xgexhkkqcs ) View more
ASH2025	Not Applicable	Hematologic Neoplasms	2,683	conventional GVHD prophylaxis + immunosuppressive agent	qdtilklcqg(umiedmpelz) = cfyfailswy cihsocgvfq (bfvhxpkbdv, 0.95 - 1.31) View more	Positive	06 Dec 2025
				conventional GVHD prophylaxis	-
NCT04150497 (BALLI-01, Company_Website) Manual	Phase 1/2	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma \| Refractory B Acute Lymphoblastic Leukemia Third line CD22 Positive	40	UCART22 + Alemtuzumab	adyizvxtde(ygdmoxuorj) = yjsoboregt zosniwcliy (geylsnqtut ) View more	Positive	16 Oct 2025
				UCART22 + Alemtuzumab (Process 1)	adyizvxtde(ygdmoxuorj) = gzdgxssesq zosniwcliy (geylsnqtut ) View more
NCT00920972 \| NCT03128996 (Pubmed \| Transplant Cell Ther)	Phase 2	Refractory Severe Aplastic Anemia	22	Alemtuzumab+fludarabine+melphalan±thiotepa (MSD/unrelated/haploidentical)	msybdfaedb(wxtqthgwvh) = Complications before day +180 were primarily transient viral reactivations. Thyroid and ovarian hypofunction were the commonest effects noted at long-term follow-up. wchtpypvxi (xlnorcbclk )	Positive	01 Sep 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis